基于FDA不良事件报告系统 (FAERS) 的阿巴洛帕拉提德的现实世界药监测研究
1Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430000, Hubei Province, China.
概括
使用FDA数据评估了阿巴洛帕拉提德 (ABL) 的安全信号. 虽然大多数不良事件是预期的,但患者年龄和早期发生 (0-7天) 与严重程度有关,有助于缓解临床风险.
科学领域:
- 药监和药物安全 药监和药物安全
- 内分泌学 在内分泌学.
- 骨质疏松症的治疗方法
背景情况:
- 阿巴洛帕拉提德 (ABL) 是FDA批准的与甲状腺激素相关的类类似物,用于骨质疏松症.
- 关于ABL在大量人群中的长期安全性和耐受性的现实数据有限.
- 这项研究旨在使用FDA药监数据评估与ABL相关的安全信号.
研究的目的:
- 对阿巴洛帕拉提德进行全面的安全信号评估.
- 为了识别和描述与阿巴洛帕拉提德使用相关的不良事件.
- 为医疗保健专业人员提供见解,以减轻临床实践中的风险.
主要方法:
- 从2017年第二季度到2022年,FDA不良事件报告系统 (FAERS) 数据库的数据挖掘.
- 使用多个统计算法 (ROR,PRR,BCPNN,MGPS) 进行信号检测.
- 进行严重和不严重病例的比较,并分析了患者的年龄和事件发生的时间框架.
主要成果:
- 分析了8,470,497份报告,其中11,487份将ABL确定为主要的可疑药物.
- 检测到99个符合所有四个算法的信号,包括35个意想不到的信号 (例如,生长疼痛,耳声,视力敏度下降).
- 患者年龄与AE严重程度的增加有关 (p < 0.001),最常见的AE发生在0-7天内.
结论:
- 这项研究增强了对阿巴洛帕拉提德在现实环境中的安全概况的理解.
- 确定了特定的意想不到的不良事件和风险因素,如患者年龄和早期发病.
- 这些发现支持持续的药物监测,并帮助临床医生管理与阿巴洛帕拉提德相关的风险.
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
相关概念视频
01:19Pharmacovigilance
889
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
889
01:25Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
01:26Drug Administration and Therapy Phases: Overview
532
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
532
01:11Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K